BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6144367)

  • 1. Dopamine D2 receptors in substantia nigra in schizophrenia.
    Owen R; Owen F; Poulter M; Crow TJ
    Brain Res; 1984 May; 299(1):152-4. PubMed ID: 6144367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.
    Kornhuber J; Riederer P; Reynolds GP; Beckmann H; Jellinger K; Gabriel E
    J Neural Transm; 1989; 75(1):1-10. PubMed ID: 2563750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
    Wong DF; Wagner HN; Tune LE; Dannals RF; Pearlson GD; Links JM; Tamminga CA; Broussolle EP; Ravert HT; Wilson AA; Toung JK; Malat J; Williams JA; O'Tuama LA; Snyder SH; Kuhar MJ; Gjedde A
    Science; 1986 Dec; 234(4783):1558-63. PubMed ID: 2878495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D1 and D2 dopamine receptors in human substantia nigra: localization and the effect of aging.
    De Keyser J; De Backer JP; Vauquelin G; Ebinger G
    J Neurochem; 1991 Apr; 56(4):1130-3. PubMed ID: 1825842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain.
    Mjörndal T; Winblad B
    Med Biol; 1986; 64(6):351-4. PubMed ID: 2881030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in D2 dopamine receptors in the substantia nigra after chronic (-)-sulpiride treatment.
    Stefanini E; Frau M; Gessa GL
    Brain Res; 1991 Aug; 555(2):340-2. PubMed ID: 1834311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation between the presynaptic dopamine-sensitive adenylate cyclase and [3H]spiperone binding sites in rat substantia nigra.
    Quik M; Emson PC; Joyce E
    Brain Res; 1979 May; 167(2):355-65. PubMed ID: 36204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
    Piggott MA; Perry EK; Marshall EF; McKeith IG; Johnson M; Melrose HL; Court JA; Lloyd S; Fairbairn A; Brown A; Thompson P; Perry RH
    Biol Psychiatry; 1998 Oct; 44(8):765-74. PubMed ID: 9798081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Nord J Psychiatry; 2010 Aug; 64(4):233-8. PubMed ID: 20629610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics.
    Mita T; Hanada S; Nishino N; Kuno T; Nakai H; Yamadori T; Mizoi Y; Tanaka C
    Biol Psychiatry; 1986 Dec; 21(14):1407-14. PubMed ID: 2947636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action.
    Reynolds GP; Rossor MN; Iversen LL
    J Neural Transm Suppl; 1983; 18():273-7. PubMed ID: 6135746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D-1 and D-2 receptors in Huntington's disease.
    Cross A; Rossor M
    Eur J Pharmacol; 1983 Mar; 88(2-3):223-9. PubMed ID: 6221936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
    Geula C; Slevin JT
    Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
    Joyce JN; Lexow N; Bird E; Winokur A
    Synapse; 1988; 2(5):546-57. PubMed ID: 2973147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and typical antipsychotics.
    Ross DE
    Am J Psychiatry; 2004 Oct; 161(10):1925-6. PubMed ID: 15465996
    [No Abstract]   [Full Text] [Related]  

  • 18. Distribution of D1 and D2 dopamine receptors in the basal ganglia of the cat determined by quantitative autoradiography.
    Beckstead RM; Wooten GF; Trugman JM
    J Comp Neurol; 1988 Feb; 268(1):131-45. PubMed ID: 2964456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors.
    Cross AJ; Crow TJ; Owen F
    Psychopharmacology (Berl); 1981; 74(2):122-4. PubMed ID: 6791218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
    Hall MD; Jenner P; Kelly E; Marsden CD
    Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.